Nirmatrelvir

Treatment of COVID-19

Nirmatrelvir is prescribed to treat mild-to-moderate COVID-19 in people who have received a positive viral test result. It is specifically intended for individuals who are at a high risk of the disease progressing to a severe stage, which could lead to hospitalization or death.

This medication is authorized for use in:

• Adults.
• Children 12 years of age and older who weigh at least 88 pounds (40 kilograms).

Timing and Administration

For the treatment to be effective, it must be started as soon as possible after a COVID-19 diagnosis and within five days of the first symptoms appearing. Nirmatrelvir is always taken in combination with another medication called ritonavir. The ritonavir helps maintain the necessary levels of nirmatrelvir in the body for a longer period.

Limitations of Use

Nirmatrelvir is not used in every situation involving COVID-19. Its use is limited by the following:

• It is not used to prevent COVID-19 before or after being exposed to the virus (pre-exposure or post-exposure prophylaxis).
• It is not used to treat patients who already require hospitalization due to severe or critical COVID-19.
• It is not authorized for use for longer than five consecutive days.

Mechanism of Action

Nirmatrelvir is a type of medicine known as a protease inhibitor. It is designed to target the SARS-CoV-2 virus, which is the virus that causes COVID-19.

To reproduce and spread, the virus must create new viral particles. This process requires a specific enzyme called a protease. The protease acts like a pair of molecular scissors, cutting long protein chains into smaller, functional pieces that the virus uses to build its structure. Nirmatrelvir works by:

• Binding to the main protease enzyme of the virus.
• Blocking the enzyme's ability to cut protein chains.
• Preventing the virus from completing its replication cycle.

By stopping the virus from making copies of itself, the medication helps the body's immune system manage the infection and reduces the amount of virus present in the system.

The Role of Ritonavir

Nirmatrelvir is typically taken in combination with another medication called ritonavir. While ritonavir does not fight the virus directly, it acts as a booster. It slows down the process by which the liver breaks down nirmatrelvir, ensuring that the antiviral medicine stays in the bloodstream at a high enough concentration for a longer period to be effective.

Common Side Effects

The most frequently reported side effects when taking nirmatrelvir with ritonavir include:

• Altered sense of taste (often described as a metallic or bitter taste)
• Diarrhea
• Muscle aches
• Increased blood pressure

Serious Side Effects

Seek medical attention immediately if you experience any of the following serious symptoms:

• Allergic reactions: Signs may include skin rash, hives, difficulty swallowing or breathing, or swelling of the lips, tongue, or face.
• Liver problems: Symptoms include yellowing of the skin or the whites of the eyes (jaundice), dark-colored urine, pale stools, nausea, loss of appetite, or pain in the upper right side of the stomach area.

In some cases, patients may experience a return of COVID-19 symptoms (rebound) after finishing the five-day course of treatment. If symptoms return or worsen after you have completed the medication, contact a healthcare professional.

Drug Interactions

Nirmatrelvir is co-administered with ritonavir, a drug that significantly affects how the body processes many other medications. This can lead to serious or life-threatening reactions or may cause other drugs to be less effective. Healthcare providers typically perform a comprehensive review of all current prescriptions, over-the-counter medicines, and herbal supplements, such as St. John's wort, before treatment begins.

Allergic Reactions

Serious allergic reactions, including anaphylaxis and angioedema, have been reported in patients taking this medication. Symptoms may include hives, difficulty swallowing or breathing, swelling of the lips, tongue, or throat, and severe rash. If an allergic reaction occurs, the medication is typically discontinued immediately.

Liver and Kidney Considerations

• Liver Health: Cases of liver enzyme elevations and clinical hepatitis have occurred. Caution is used in patients with pre-existing liver diseases, liver enzyme abnormalities, or hepatitis.
• Kidney Health: Because the medication is cleared through the kidneys, dose adjustments are necessary for patients with moderate kidney impairment. It is generally not recommended for individuals with severe kidney disease.

HIV-1 Resistance

Because ritonavir is also used as a treatment for HIV-1, there is a risk that the HIV-1 virus may develop resistance to certain HIV medications in people with undiagnosed or uncontrolled HIV-1 infection. This could make future HIV treatments less effective.

Pregnancy and Lactation

There is limited data regarding the use of this medication during pregnancy. It is generally only used if the potential benefits outweigh the potential risks to the fetus. Additionally, individuals are often advised to use effective non-hormonal contraception during treatment, as ritonavir may reduce the effectiveness of hormonal birth control.

Pregnancy

There are currently no adequate human studies to determine if nirmatrelvir poses a risk to a developing fetus. In animal studies, no significant developmental issues were observed at doses higher than those used in humans. Because the risks are not fully known, this medication is typically used during pregnancy only when the potential benefits outweigh the potential risks to both the parent and the fetus.

If you are pregnant or planning to become pregnant, talk to your doctor about your treatment options. It is also important to note that nirmatrelvir is taken with ritonavir, which may decrease the effectiveness of hormonal birth control pills. Your healthcare provider may recommend using an additional or alternative method of contraception during treatment.

Breastfeeding

It is not known whether nirmatrelvir passes into breast milk or how it might affect a nursing infant. Due to the lack of data and the potential for side effects, breastfeeding is generally not recommended during treatment and for seven days after the last dose. Consult your healthcare provider to decide whether to pause breastfeeding or use an alternative feeding method during this time.

Dosage Forms

Nirmatrelvir is available as a tablet for oral administration. It is co-packaged with ritonavir tablets, and both medications must be taken together.

Packaging

The tablets are provided in blister cards. These cards are designed to assist patients in taking the required tablets for each dose.

FDA Approval Status

The U.S. Food and Drug Administration (FDA) approved nirmatrelvir co-packaged with ritonavir in May 2023. It was the first oral antiviral treatment for COVID-19 to receive full FDA approval for adults. This approval is specifically for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe disease, including hospitalization or death.

Emergency Use Authorization

Before its full approval for adults, the medication was granted an Emergency Use Authorization (EUA) in December 2021. The EUA remains in effect for eligible pediatric patients aged 12 years and older who weigh at least 40 kilograms (about 88 pounds) and are at high risk for severe COVID-19.

Regulatory Limitations and Requirements

• The medication is not authorized for the prevention of COVID-19 either before or after exposure to the virus.
• It is not approved for use in patients who require hospitalization due to severe or critical COVID-19.
• Treatment must be initiated as soon as possible after a COVID-19 diagnosis and within five days of the start of symptoms.
• The FDA requires that the two medications (nirmatrelvir and ritonavir) be taken together for the treatment to be effective.

Use in COVID-19 Treatment

Nirmatrelvir is an oral antiviral medication used to treat mild-to-moderate COVID-19. It is specifically indicated for patients who have a positive viral test and are at high risk for progression to severe disease, including hospitalization or death. This includes adults and pediatric patients 12 years of age and older who weigh at least 40 kilograms (about 88 pounds).

Mechanism of Action

Nirmatrelvir is a SARS-CoV-2 main protease (3CLpro) inhibitor. It works by interfering with the virus's ability to replicate within the body. By stopping the virus from multiplying, the medication helps lower the viral load and reduces the risk of the infection becoming life-threatening. It is always administered with ritonavir, which acts as a booster to keep nirmatrelvir at therapeutic levels in the body.

Treatment Guidelines

• Timing: Treatment should begin as soon as possible after a positive COVID-19 test and within five days of symptom onset.
• Duration: The typical course of treatment lasts for five days.
• Limitations: Nirmatrelvir is not authorized for the pre-exposure or post-exposure prevention of COVID-19. It is also not intended for patients who require immediate hospitalization due to severe COVID-19 symptoms.